Amoxapine is a tricyclic antidepressant used for the treatment of psychotic depression. Psychotic depression is generally refractory to medical treatment and plural medicines are usually prescribed concurrently.
The treatment of psychotic depression is different from other depression. TCA mono-therapy such as amoxapine alone is usually recommended for mildly affected patients, while combination therapy such as TCA together with other antipsychotic agents are commonly applied for patients with severe symptoms10). However, in cases of symptomatic treatment for patients with complicated psychotic depression but without accompanying severe symptoms, combination therapies are also frequently required11). In addition, it was reported recently that combination therapy for the treatment of psychotic depression is more effective than TCA mono-therapy12) . With the current trend of medication by using selective serotonin receptor antagonist (SSRI) and selective noradrenaline receptor antagonist (SNRI) for the treatment of psychotic depression, amoxapine remains one of the important antidepressant pharmacotherapies in the clinical setting.
Medication for patients with psychotic depression commonly involves multiple drugs used concurrently, including TCA, other antipsychotic drug and SSRI. TCA have been prescribed in the treatment of depression for a long time, and it is well known that metabolism of some of the TCA is mediated by the cytochrome P450 (cYP) enzyme13- 19 ). In the current multi-drug therapies used for patients with psychotic depression, there are many reports of drug-drug interactions between TCA and the other drugs described above20, 21, 24) However, most of the reports describe the inhibition of TCA metabolism by the co-administrated medicine. The inhibitory potential of TCA on CYP-mediated drug metabolism has not been extensively described, and risk assessments for multiple drug therapy in these patients have not considered factors such as unexpected changes in pharmacokinetic parameters and/or pharmacodynamics of the drugs. Amoxapine is frequency used for the treatment of psychotic depression and it is also commonly prescribed to be used concurrently with other antipsychotic drugs. However, there is no data evaluating the effect of amoxapine on CYP enzyme-mediated drug metabolism. Such information is necessary to properly assess the therapy risks and therefore to avoid adverse reactions in patients being treated for psychotic depression.
This study aimed to assess the effect of amoxapine on five CYP enzymes ( CYP1A2, 2C9, 2C19, 2D6 and 3A4), which are important clinically due to their roles in drug metabolism. In addition, the influence of amoxapine metabolites on these CYP enzymes was determined.
Materials and Methods

Chemicals and reagents
Amoxapine was purchased from ICN Co., Ltd. (Irvine, CA, U.S.A). Bufuralol, 1'-hydroxybufuralol, S-warfarin, 7-hydroxywarfarin, l'-hydroxymidazolam, ethoxyresorufin S-mephenytoin and 4-hydroxymephenytoin were purchased from Daiichi Pure Chemicals Co., Ltd. (Tokyo). Resorfin was obtained from Sigma Chemical Co. (St. Louis, MO, U.S.A). Midazolam was generously donated by Nippon Roche K.K. Inc (Osaka). j9 -nicotinamide adenine dinucleotide phosphate (NADPH ), G-6-P and G-6-P DH were purchased from Oriental Yeast Co., Ltd. (Tokyo).
All other chemicals and reagents used were of the highest commercially available quality.
Enzyme sample
Human liver microsomes (pooled fraction from 10 patients) were obtained from the Human and Animal Bridging Research Organization (Non-profit organization) (Lot NO. The flow rate of the mobile phase was 1 ml/min and UV absorbance was monitored at 204 nm. The enzyme activity was calculated from the 4'-hydroxymephenitoin formation rates.
Bufuralol 1'-hydroxylation activity
The incubation mixtures (final volume, 150 pl) consisting of a NADPH generating system (1 mM NADPH, 8 mM G-6-P and 0.4U G-6-P DH), 15 pg of microsomal protein, 10 pM bufuralol and 500 pM MgC12 and with or without amoxapine in 90 mM sodiumpotassium phosphate buffer (pH 7.4) was incubated at 37°C for 15 minutes. The enzymatic reaction was terminated by 15 p1 of 60% perchloric acid on ice. The resulting samples were centrifuged at 12,000 X g for 5 min. The supernatant was applied onto an HPLC system. The separation of 1'-hydroxybufuralol was carried out using an CAPCELLPAK C18 SG 120 (4.6 mm X 25 cm) ODS column (Shiseido Co., Ltd, Tokyo). Elution was performed with 20 mM NaC104 (pH2.5): acetonitrile (70: 30). The flow rate of the mobile phase was 1 ml/min and 1'-hydroxybufuralol was detected by fluorometric detection wavelengths at 252 nm and 302 nm, excitation and emission, respectively. Enzyme activity was calculated from the 1'-hydroxybufuralol formation rates from bufuralol. HPLC system HPLC analyses of extracts of microsomal incubations were performed using a JASCO HPLC system (JASCO, Tokyo) with an intelligent pump ( 880-PU ), automatic sample injector (851-AS), degasser (880-50) and system controller (802-SC). Detection was carried out using an SPD-6A (Shimadzu Co., Kyoto) and L7485 (Hitachi Co., Ltd, Tokyo), UV-detector and fluorescence detector. Data calculation was performed on a C-R7A integrator (Shimadzu Co., Kyoto). 
Preincubation-dependent inhibition of amoxapine on CYP enzymes
To evaluate the inhibitory effect of amoxapine metabolites on CYP enzymes activity, a pre-incubation study was conducted. Amoxapine concentrations of 50 ACM for CYP1A2, 2C9, 2C19, and 3A4, and 10 pM for CYP2D6, were used. Pre-incubations were carried out for 10 to 30 min, with or without the NADPH generating system, before commencement of each CYP-dependent enzyme reaction.
Results
Inhibitory effects of amoxapine on CYP enzyme activities in human liver microsomes
To evaluate the inhibitory potency of amoxapine on CYP enzymes, the concentrationinhibition relationship was examined. Amoxapine was a potent inhibitor of CYP2D6 and 3A4 activity with apparent IC50 values of 25.37 and 76.87 ACM, respectively. In contrast, amoxapine demonstrated only a weak inhibitory effect on CYP2C9 and CYP2C 19 enzyme with IC50 values of 236.69 and 148.40 pM, respectively. A negligible inhibitory effect was observed on CYP 1 A2 (Fig. 1) .
Dixon plot analysis of the effect of amoxapine on CYP2D6 in human liver microsomes
Dixon Plot analysis was also performed to confirm the inhibitory potency and mechanism of action of amoxapine on CYP2D6 and CYP3A4. Amoxapine was a competitive inhibitor 
Influence of pre-incubation with amoxapine on CYP enzyme activity in human liver microsomes
To evaluate the participation of amoxapine metabolites in the inhibition of CYP enzyme-mediated drug metabolism, pre-incubation studies were performed.
However, no significant gain in the inhibitory potency of amoxapine was observed (Fig. 3) . 
Discussion
In the present study, we investigated the inhibitory potency of amoxapine on the CYP enzymes, CYP 1 A2, 2C9, 2C19, 2D6 and 3A4. Competitive inhibition was observed with CYP2D6 and 3A4, while only a marginal effect was observed with CYP1A2, 2C9 and 2C19. In general, TCAs are mainly metabolized to N-demethylated and hydroxylated forms [13] [14] [15] [16] [17] [18] [19] . The hydroxylation reaction is mainly mediated by CYP2D613, 14, 17, 19) , and several CYPs are involved in the N-demethylation 15"6,1 8,19) Venkatakrishnan et al. reported that nortiptyline, classified in the same TCA group as amoxapine, is metabolized to 10-hydroxynortriptyline by CYP2D6 with an apparent Km value of 2.1 pM and CYP3A4 with an apparent Km value of 37.4 pM13). In addition, amitriptyline N-demethylation is mediated by CYP3A4, CYP 1 A2, CYP2D6, and CYP2C916) . It is also reported that amoxapine is metabolized to 7-hydroxyamoxapine and 8-hydroxyamoxapine2,22), however there is not much information about the corresponding enzyme mediating this biotransformation. The data presented here showed that amoxapine inhibits the CYP2D6 and CYP3A4 enzymes competitively. The major metabolic pathway converting amoxapine to 7-or 8-hydroxyamoxapine is aromatic hydroxylation, as for other TCAs. Together with results from other studies, our results indicate that 7-or 8-hydroxylation of amoxapine may be catalyzed mainly by CYP2D6 and partially by CYP3A4.
It has been reported that TCAs are metabolized by several CYP isozymes 13-19 and also that several drug-drug interaction between TCAs and co-administered medicine occur2o, 21, 23-25). Bergstom et al23) reported that fluoxetine had potently lowered the systemic clearance of imipramine by 1/10.
Another report showed that paroxetine administration prolongs the elimination half life of imipramine by approximately 50% 21 Since TCAs inhibit CYP2D6-mediated enzyme activity26,27), it is not surprising that numerous interactions between TCAs and commonly used drugs, which are categorized as substrates of CYP2D6, has been observed. However, the exact inhibitory potency of TCAs on CYP2D6 has not been extensively studied. It has been reported that fluoxetine and paroxetine, which are SSRIs, also inhibit CYP2D6 activity in vivo21, 23, 28) and in vitro26), with Ki values of 0.6 and 0.15 pM, respectively. These Ki values are lower than the Ki values of TCAs described above. Furthermore, fluoxetine and paroxetine are widely distributed throughout body tissues21,29), and have a Cmax level of approximately 16029 and 40 nM21 ), respectively. These blood concentrations are close to their apparent Ki values estimated in vitro. In contrast, imipramine, which also is widely distributed throughout body tissue (Vd value= 28-611/kg) , has a Cmax value of approximately 70 nM2U, which is lower than the Ki value calculated from in vitro studies. Although it is hard to extrapolate these data directly to in vivo drug-drug interactions, imipramine probably does not affect the metabolism of the substrate of CYP2D6.
Amoxapine has been widely prescribed to patients with depression for a long time. However, there is scarce data on the drug-drug interactions between amoxapine and co-administrated medicines. Amoxapine is usually administered orally with a dose regimen of 25-75 mg daily in Japan. In serious patients, the dosage may be increased up to 300 mg daily2). Amoxapine is widely distributed throughout all tissues of the body2, 22), Greenblatt et al reported that the concentration of amoxapine in tissue was 10 times higher than the plasma concentration 5 min after the intravenous administration in animal experiments30). Amoxapine reached maximal serum levels of 0.14 ACM between 1 and 1.5 hr after a single oral dosage (50 mg) 2,22) . Similar to other TCAs, amoxapine takes several weeks to have a therapeutic effect. During this long-term period, accumulation of amoxapine in the body tissues may occur. However, the apparent Ki values of amoxapine for CYP2D6 and CYP3A4 estimated in the present study were higher than the drug concentration in plasma commonly using for the treatment of psychotic depression. Therefore, these results indicate that amoxapine might not inhibit the CYP2D6 and CYP3A4 enzyme-mediated drug metabolism of the co-administered medicines in viva.
On the other hand, it has been reported that amoxapine is metabolized to the major metabolites, 7-hydroxyamoxapine and 8-hydroxyamoxapine in the liver2, 22), These metabolites have pharmacological effects similar to amoxapine2, 22) .
The active metabolite, 8hydroxyamoxapine appears immediately in plasma and is eliminated quite slowly from the blood, with an average elimination half-life of 30.8 hr22). We proposed that these metabolites might have an influence on the CYP enzyme-mediated drug metabolism. Unfortunately, it is impossible to obtain these metabolites. Therefore, we tried a pre-incubation study to evaluate the effects of these metabolites on CYP enzyme activity. The inhibitory potency of amoxapine was not increased by pre-incubation with or without NADPH.
This result suggested that amoxapine metabolites do not affect the CYP enzyme-mediated drug metabolism. However, the technique used could not adequately represent the production of Effect of Amoxapine 
